Paul Wallace, MD
Dermatology · Beverly Hills, CANPI 1063494474
Payments from drug & device makers
Across 1,231 payments — averaging $5752.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$2M
- AbbVie$1.4M
- Pfizer$958K
- Amgen$938K
- Janssen Research & Development, LLC$681K
- E.r. Squibb & Sons, L.L.C.$292K
- plus $734K from 28 others
Across 4 payments — averaging $8492.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$34K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 41 | $2,039,281 |
| AbbVie | 292 | $1,439,452 |
| Pfizer | 134 | $957,780 |
| Amgen(2 entities) | 57 | $937,909 |
| Janssen Research & Development, LLC | 37 | $680,808 |
| E.r. Squibb & Sons, L.L.C. | 21 | $292,168 |
| Kiniksa Pharmaceuticals, Ltd. | 109 | $251,691 |
| Incyte Corporation | 41 | $183,567 |
| UCB, Inc. | 220 | $128,881 |
| Novartis | 100 | $74,212 |
| Bristol Myers Squibb | 36 | $36,009 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $28,543 |
| Dermira, Inc. | 6 | $14,127 |
| Arcutis Biotherapeutics, Inc. | 20 | $12,108 |
| Boehringer Ingelheim | 3 | $1,351 |
| Sun Pharmaceutical Industries Inc. | 16 | $533 |
| Johnson & Johnson | 22 | $523 |
| LEO Pharma AS | 1 | $450 |
| Dermavant Sciences, Inc. | 10 | $432 |
| Sanofi | 17 | $428 |
| Lilly USA, LLC | 13 | $350 |
| Botanix SB Inc | 3 | $179 |
| Galderma Laboratories, L.p. | 8 | $155 |
| LEO Pharma Inc. | 6 | $138 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $100 |
| Regeneron Healthcare Solutions, Inc. | 2 | $70 |
| Genentech USA, Inc. | 3 | $68 |
| Almirall LLC | 2 | $55 |
| DUSA Pharmaceuticals, Inc. | 2 | $52 |
| Verrica Pharmaceuticals Inc. | 2 | $48 |
| Organon | 2 | $35 |
| Janssen Scientific Affairs, LLC | 1 | $32 |
| Stemline Therapeutics Inc. | 1 | $30 |
| Mayne Pharma Commercial LLC | 1 | $23 |
How this compares
$7,081,588 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other dermatology in Beverly Hills
- Vivian LaquerIrvine$20.9M
- Howard SofenLos Angeles$16.1M
- Raja SivamaniSacramento$11.8M
- Jennifer SoungSanta Ana$10.3M
- Stacy SmithEncinitas$7.9M
- Paul YamauchiSanta Monica$7.8M
- Navid EzraThousand Oaks$7.8M
- April ArmstrongLos Angeles$6.2M
- David RayhanHuntington Beach$5.2M
- Neal BhatiaSan Diego$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.